A CAR against CAR for unintended consequences

Research output: Contribution to journalReview article

Abstract

In this issue of Blood, Ruella and colleagues report the development of a chimeric antigen receptor (CAR) that could target anti-CD19 CAR T cells (CAR191 T) used for therapy of B-cell malignancies as well as leukemic B cells inadvertently transduced with anti-CD19 CAR (CAR191 B).1

Original languageEnglish (US)
Pages (from-to)460-462
Number of pages3
JournalBlood
Volume135
Issue number7
DOIs
StatePublished - Feb 13 2020

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this